A Rare Childhood Disease Finally Mapped 

For families of children born with alternating hemiplegia of childhood, the questions begin almost immediately: Will it get worse? How long do we have? What should we prepare for?  

The clearest answers yet are emerging and changing how doctors and families understand the course of a rare neurological disorder.  

The research traces the natural history of alternating hemiplegia of childhood, or AHC, a condition so rare that it affects roughly one in a million children worldwide. A landmark study by Duke University School of Medicine clarifies what clinicians could only guess and reinforces why early intervention and careful monitoring may be critical.  

“This is the kind of information families have been asking about for decades,” said senior study author Mohamad Mikati, MD, professor of pediatrics and neurobiology who has helped build one the most robust AHC clinics in the world at Duke Health. “We finally have a clearer picture of the trajectory.”  

A disorder defined by uncertainty 

AHC typically appears in infancy, often before a child’s first birthday. It is marked by recurring episodes of paralysis, affecting one side of the body or the other, or both — along with seizures, abnormal movements, cognitive impairment, and development delays.  

For decades, doctors could diagnose AHC only by its symptoms. In the 1990s, Mikati identified the first hereditary family with the disease, proving it was genetic and launching national AHC patient registries, including one at Duke. But families were still left without answers about why it occured, how fast it progressed or what families should expect long term.  

That began to change in 2012, when Mikati joined an international team led by former Duke geneticist David Goldstein, PhD, to identify mutations in the ATP1A3 gene as the cause of AHC in most patients. The gene affects a critical neural “pump” needed to meet the brain’s energy demands.  

But understanding the genetic cause did not immediately answer the most pressing question: What happens over a lifetime?  

To find out, researchers evaluated 115 patients ranging from infancy to 46 years old, drawing from nine medical centers across five countries. Using standardized neurological and developmental assessments, and following many patients for up to three additional years, the team asked a fundamental question: Does AHC progress and if so, when?  

AHC does worsen over time, but not steadily throughout life. Instead, the disease appears to exert its greatest and most damaging effects during a distinct window in early childhood — between ages 1 and 5.  

During those years, children experienced significant declines in intellectual functioning and non-episodic disability — the everyday cognitive and physical challenges that exist outside of sudden paralysis attacks. Adaptive behaviors, including communication and daily living skills, also worsened.  

After age 5, however, that decline largely stabilized. Intellectual and functional scores did not continue to deteriorate through later childhood and adulthood.  

For families, that distinction matters.  

“It’s a disease with a critical early phase that defines much of the long-term outcomes.”  said lead study author Shital Patel, MD, a pediatric neurologist specializing in epilepsy at Duke Health.

What gets better — and what doesn’t 

Not every part of the disease followed the same pattern.  

Underlying motor impairment, which is difficulty with movement, remained largely stable across age groups. So did dystonia, the involuntary muscle contractions that can twist the body into painful positions.  

There was, however, an encouraging finding.  

The severity of paralysis episodes improved after age 5. Attacks did not disappear, but they became less intense and less disabling over time.  

For parents who spend early childhood bracing for sudden collapses, hospital visits and emergency medications, that nuance offers a measure of relief. While baseline challenges often persist, some of the most frightening symptoms may ease as children grow older.  

Predicting the future 

The natural history study which included additional Duke authors Lyndsey Prange, April Boggs, Joan Jasien, Beiyu Liu, and Hwanhee Hong, also identified key factors that influence long-term outcomes — information that could transform how clinicians counsel families.  

Children who developed epilepsy fare significantly worse across multiple measures, including intellectual ability, motor function, and non-paroxysmal disability. Early severity mattered as well: children with greater impairment in early life were more likely to experience outcomes later.  

Genetics also played a role. Specific ATP1A3 mutations were linked to characteristic patterns of severity. The D801N mutation was associated with more severe episodic disability, while the E815K mutation correlated with greater intellectual impairment.  

Over time, those distinctions may help doctors tailor monitoring strategies, prioritize seizure control, and design personalized therapies.  

Perhaps more urgently the study addressed a question many families are afraid to ask outright: is AHC life-threatening?  

Researchers identified a mortality rate of 1.12 deaths per 100 patient years. Sudden unexpected death in epilepsy, or SUDEP, occurred at a rate of 6.5 deaths per 1,000 patient years — a meaningful and concerning figure for a pediatric neurological condition.  

Those findings highlight the importance of epilepsy management and long-term monitoring, not just to improve the quality of life, but to save lives.  

Why this moment matters  

Rare diseases often suffer from a lack of long-term data. Without knowing how a condition unfolds, doctors struggle to guide families; researchers lack endpoints for clinical trials and funding agencies underestimate urgency. 

By defining when AHC progresses most sharply, identifying predictors of outcome and documenting mortality risk, this study advances the medical understanding of the disease.  

It also reframes AHC itself, Patel said, not as a static disorder punctuated by isolated episodes, but as a condition with progressive elements concentrated in early childhood.  

That shift is already influencing research. Mikati said Duke scientists are now exploring gene-targeted therapies and early-intervention strategies designed specifically for that vulnerable window.  

Families who pushed science forward  

Behind the data are families who refused to accept uncertainly as an answer.  

Jeff and Renee Wuchich, of Rolesville, NC, whose son Matthew was diagnosed with AHC in 2008 at 18 months old, spent more than a year being told his symptoms didn’t make sense. Doctors suggested epilepsy. Todd’s paralysis. Anything but what it was. 

After repeatedly pressing for answers, Matthew’s neurologist referred the family to UNC Hospitals for further evaluation. There, a paralysis episode occurred during an appointment, and Matthew was admitted for a series of tests and blood work. 

“He said the only thing left that it could be is alternating hemiplegia of childhood,” Renee remembers. At the time, they knew 200 cases in the world.  

“He told us, ‘I have no advice for you. We don’t know if he’ll walk or talk, but we’ll support you in every way we can.’” Still, the diagnosis mattered.  

“We finally had a neurologist who agreed we weren’t crazy,” Renee said. “That what we were seeing was really happening.”  

The family was propelled into advocacy. In 2011, after Mikati joined Duke, the couple helped organize a family gathering in Raleigh that would become a turning point for the field.  

“We helped recruit families to submit genetic samples to Duke,” said Jeff Wuchich, a therapist and pastoral counselor. “That effort led directly to the discovery that mutations in the ATP1A3 gene causes most cases of AHC.”  

From there, the Duke AHC clinic at Duke Children’s Hospital and the natural history study, was launched.  

“The natural history will help families initiate treatments earlier,” Renee said of occupational, speech and physical therapy to help children improve mobility and communication. “It also gives them a clearer understanding of the disease so they can better inform caregivers, schools, and therapists.” 

The couple have stepped away from leadership roles in the nonprofit CureAHC to focus more fully on Matthew’s care, but the foundation they created and helped build continues to thrive.  

Matthew will turn 19 this summer. He walks, talks, loves baseball and plays in a special needs league. Developmentally, he functions closer to a young child, but his parents emphasize his independence. 

“He has a charming personality,” his dad says. “He has a faith practice. He knows what he likes and doesn’t like. AHC is something Matthew has — it’s not who he is.”  

Shantell Kirkendoll is a senior science writer and managing editor at the Office of Strategic Communications in the Duke University School of Medicine.  

Eamon Queeney is assistant director of multimedia and creative at the Office of Strategic Communications in the Duke University School of Medicine.

Mark Dolejs is senior visual storyteller in the Office of Strategic Communications at the Duke University School of Medicine.